#China #Shenzhen #Clinical Trial #Kexing Biopharm #GB10 Injection

Kexing Biopharm's Innovative GB10 Injection: A New Hope for Macular Degeneration

Shenzhen Kexing Biopharmaceutical Co., Ltd., a subsidiary of Kexing Biopharm, has made a significant advancement in ophthalmic treatments with the commencement of their Phase I clinical trial for GB10 Injection, a novel therapy targeting neovascular age-related macular degeneration (nAMD). The first patient was recently dosed in this promising study, which aims to evaluate the safety and efficacy of this innovative drug formulation.

A Breakthrough in Ophthalmic Treatment

GB10 Injection is a high-concentration ophthalmic drug that showcases Kexing's commitment to revolutionize care for patients suffering from nAMD, a leading cause of blindness in adults over the age of 50 globally. As the aging population increases, coupled with lifestyle factors such as increased screen time, the prevalence of nAMD is rising, leading to a greater demand for effective and accessible treatment options.

This drug stands out due to its bispecific antibody design which targets both vascular endothelial growth factor (VEGF) and Ang-2. At a concentration of 140 mg/mL, GB10 allows for a reduced injection volume while maintaining a higher dosage. This is expected to lead to an extended dosing interval, with the potential for a regimen of only once every four months, thus improving patient compliance significantly. The preclinical studies demonstrate that GB10 shows international competitiveness, with promising biological activity and remarkable in vivo efficacy in preclinical models.

Addressing Clinical Pain Points

One of the primary challenges in treating nAMD has been the requirement for frequent injections, which can lead to poor patient adherence and increasing burden on healthcare systems. By extending the dosing interval, GB10 Injection directly addresses these critical pain points. The development of such innovative therapies underscores the need for pharmaceutical advancements that can alleviate the burden on both patients and healthcare providers.

Kexing Biopharm's Expanding Portfolio

Beyond the development of GB10, Kexing Biopharm is proactive in its research and development of a dual-target antibody pipeline, while also exploring partnerships to introduce internationally developed ophthalmic products to the Chinese market. This includes potential biosimilars such as Aflibercept and Olopatadine Hydrochloride eye drops, indicating Kexing’s strategy to continually expand its global reach and drive international collaboration.

As Kexing progresses with the clinical trial of GB10 and enhances its ophthalmic product offerings, the company remains dedicated to its mission of providing high-quality, precise, and accessible treatment to patients worldwide. The alignment of their innovative strategies with global healthcare needs positions Kexing Biopharm as an emerging player in the pharmaceutical industry's landscape.

Looking Forward

The future for GB10 Injection and Kexing Biopharm appears bright as they advance through clinical trials. By adhering to their guiding principle of offering “Precise Products, Predictable Effects, Health Protection,” they aim to deliver solutions that improve patient outcomes and reshape ophthalmic treatment paradigms globally. Kexing Biopharm's initiative reflects the ongoing evolution in medicine, where innovations hold the key to enhanced care and better quality of life for patients facing serious health challenges.